The Cellular, Tissue and Gene Therapies Advisory Committee — formerly called the Biological Response Modifiers Advisory Committee — reviews and evaluates available data relating to the safety, effectiveness, and appropriate use of human cells, human tissues, gene transfer therapies, and xenotransplantation products that are intended for transplantation, implantation, infusion, and transfer in the prevention and treatment of a broad spectrum of human diseases and in the reconstruction, repair or replacement of tissues for various conditions. Members of the committee include authorities knowledgeable in the fields of cellular therapies, tissue transplantation, hematology/oncology, and human tissues and transplantation, among other specialties.
New Analysis Finds No Link Between CAR T-Cell Therapy, Secondary Cancers
February 05, 2025
REGULATORY UPDATE: Blood Community Submits Comments on HCT/P Draft Guidances
February 05, 2025
EU Approves First Chikungunya Vaccine, Expands Approval for Liso-cel
February 05, 2025